|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Phathom Pharmaceuticals, Inc. (PHAT) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
57,250,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. Co.'s primary product candidate, vonoprazan, is an oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a class of medicines that block acid secretion in the stomach. Vonoprazan has shown effects and has demonstrated clinical results as an agent in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of H. pylori infection.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
7,500 |
7,500 |
100,419 |
| Total Buy Value |
$0 |
$58,580 |
$58,580 |
$738,538 |
| Total People Bought |
0 |
1 |
1 |
4 |
| Total Buy Transactions |
0 |
3 |
3 |
12 |
| Total Shares Sold |
20,286 |
3,732,423 |
3,736,493 |
3,752,906 |
| Total Sell Value |
$191,642 |
$30,255,939 |
$30,305,472 |
$30,443,179 |
| Total People Sold |
2 |
3 |
3 |
3 |
| Total Sell Transactions |
2 |
5 |
7 |
13 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Henderson Molly |
CFO and CBO |
• – – |
2024-04-08 |
4 |
S |
$11.10 |
$38,129 |
D/D |
(3,435) |
95,263 |
|
- |
|
| Curran Terrie |
President and Chief Executive |
• • – |
2024-03-22 |
4 |
S |
$9.11 |
$153,513 |
D/D |
(16,851) |
410,784 |
|
- |
|
| Medicxi Co-Invest Iv Lp |
|
– – • |
2024-01-24 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
7,464,572 |
|
- |
|
| Takeda Pharmaceutical Co Ltd |
10% Owner |
– – • |
2024-01-24 |
4 |
S |
$8.10 |
$29,999,994 |
D/D |
(3,703,703) |
3,755,583 |
|
- |
|
| Henderson Molly |
CFO and CBO |
• – – |
2024-01-19 |
4 |
S |
$7.75 |
$48,900 |
D/D |
(6,307) |
98,698 |
|
- |
|
| Henderson Molly |
CFO and CBO |
• – – |
2023-11-20 |
4 |
S |
$7.24 |
$15,403 |
D/D |
(2,127) |
103,061 |
|
- |
|
| Parikh Asit |
Director |
– • – |
2023-11-08 |
4 |
B |
$7.80 |
$19,500 |
D/D |
2,500 |
55,000 |
2.39 |
- |
|
| Parikh Asit |
Director |
– • – |
2023-11-07 |
4 |
B |
$7.76 |
$31,040 |
D/D |
4,000 |
52,500 |
2.39 |
- |
|
| Parikh Asit |
Director |
– • – |
2023-11-06 |
4 |
B |
$8.04 |
$8,040 |
D/D |
1,000 |
48,500 |
2.39 |
- |
|
| Nabulsi Azmi |
Chief Operating Officer |
• – – |
2023-07-14 |
4 |
A |
$0.00 |
$0 |
D/D |
110,000 |
209,567 |
|
- |
|
| Curran Terrie |
President and Chief Executive |
• • – |
2023-07-14 |
4 |
A |
$0.00 |
$0 |
D/D |
200,000 |
389,671 |
|
- |
|
| Henderson Molly |
CFO and CBO |
• – – |
2023-07-14 |
4 |
A |
$1.00 |
$25,000 |
D/D |
25,000 |
95,180 |
|
- |
|
| Henderson Molly |
CFO and CBO |
• – – |
2023-06-02 |
4 |
AS |
$11.41 |
$22,368 |
D/D |
(1,960) |
68,506 |
|
- |
|
| Parikh Asit |
Director |
– • – |
2023-06-02 |
4 |
A |
$7.40 |
$111,000 |
D/D |
15,000 |
47,500 |
|
- |
|
| Kunz Heidi |
Director |
– • – |
2023-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
9,000 |
|
- |
|
| Socks David A |
Director |
– • – |
2023-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
9,000 |
|
- |
|
| Karbe Frank |
Director |
– • – |
2023-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
9,000 |
|
- |
|
| Cola Michael F |
Director |
– • – |
2023-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
18,798 |
|
- |
|
| Parikh Asit |
Director |
– • – |
2023-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
32,500 |
|
- |
|
| Stenhouse Mark |
Director |
– • – |
2023-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
9,000 |
|
- |
|
| Topper James N |
Director |
– • • |
2023-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
21,596 |
|
- |
|
| Henderson Molly |
CFO and CBO |
• – – |
2023-05-22 |
4 |
AS |
$12.87 |
$27,165 |
D/D |
(2,110) |
70,466 |
|
- |
|
| Nabulsi Azmi |
Chief Operating Officer |
• – – |
2023-04-11 |
4 |
B |
$8.26 |
$82,600 |
D/D |
10,000 |
99,567 |
2.74 |
- |
|
| Parikh Asit |
Director |
– • – |
2023-04-10 |
4 |
B |
$7.55 |
$7,550 |
D/D |
1,000 |
23,500 |
2.39 |
- |
|
| Curran Terrie |
President and Chief Executive |
• • – |
2023-04-06 |
4 |
B |
$7.82 |
$101,025 |
D/D |
12,919 |
188,290 |
2.81 |
- |
|
144 Records found
|
|
Page 1 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
